Adding glofitamab to chemotherapy for untreated mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called glofitamab (given with standard chemotherapy) for people with untreated mantle cell lymphoma. It aims to see if adding this drug helps control the cancer better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have mantle cell lymphoma that hasn't been treated before and is at an advanced stage (II bulky, III, or IV).
- Be between 18 and 75 years old.
- Be in reasonably good health, with a performance status of 2 or less (able to do light activity).
- Have adequate organ function, including blood counts, kidney, and liver function within acceptable limits.
- Agree to use effective contraception during the study and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a new immunotherapy drug called glofitamab to standard chemotherapy for aggressive lymphomas. The goal is to see if the combination is more effective at shrinking or eliminating the lymphoma.
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
This trial tests a new drug called glofitamab to see if it works better than other standard treatments for people with mantle cell lymphoma that has come back or not responded to previous therapy. It is for patients who have already tried a BTK inhibitor and at least one other treatment.
This trial tests a combination of three drugs (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma. The goal is to see if this combination works better for high-risk or older patients.
This trial tests a new drug called glofitamab for people with mantle cell lymphoma (MCL) whose cancer did not respond or came back after CAR T-cell therapy. Glofitamab is a type of immunotherapy that helps your immune system fight the cancer.
This trial tests a drug called glofitamab for people with aggressive B-cell lymphomas (like DLBCL or mantle cell lymphoma) that have come back or not responded to standard treatments. The study uses a biopsy during treatment to see how the drug is working, aiming to make treatment more personalized.
Hear when a new Ann Arbor Stage II Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.